• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by KALA BIO Inc.

    6/28/24 4:18:23 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALA alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001479419
    Kala Pharmaceuticals, Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    KALA BIO, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    KALA BIO, Inc.
    Street Address 1 Street Address 2
    1167 MASSACHUSETTS AVENUE
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    ARLINGTON MASSACHUSETTS 02476 781-996-5252

    3. Related Persons

    Last Name First Name Middle Name
    Iwicki Mark
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Bazemore Todd
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Brazzell Kim
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kharabi Darius
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Reumuth Mary
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Koven Andrew I.
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Perry Gregory D.
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Farid Marjan
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Blumenkranz Mark S.
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Rosen Howard B.
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Myers C. Daniel
    Street Address 1 Street Address 2
    1167 Massachusetts Avenue
    City State/Province/Country ZIP/PostalCode
    Arlington MASSACHUSETTS 02476
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-06-28    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $12,499,192 USD
    or    Indefinite
    Total Amount Sold $12,499,192 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    5

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    KALA BIO, Inc. /s/ Mary Reumuth Mary Reumuth Chief Financial Officer 2024-06-28

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $KALA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KALA

    DatePrice TargetRatingAnalyst
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    9/29/2025Buy → Neutral
    H.C. Wainwright
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    9/8/2025$30.00Outperform
    Mizuho
    7/11/2025$12.00Buy
    Ladenburg Thalmann
    3/30/2022Neutral → Underweight
    JP Morgan
    8/6/2021$14.00 → $11.00Buy
    HC Wainwright & Co.
    8/6/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KALA BIO Settles Approximately $10.6 million of Debt

    ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), ("KALA" or the "Company") today announced the successful completion of its loan settlement with Oxford Finance, LLC ("Oxford"), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations. As previously disclosed in the Company's Current Report on Form 8-K filed on November 25, 2025, KALA and its subsidiary Combangio, Inc., entered into a Loan Settlement Agreement with Oxford pursuant to which the Company owed Oxford $2 million to be paid pursuant to the terms of the Settlement Agreement. The Settlement Agreement was negotiated in connection with

    1/5/26 4:10:05 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

    ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("KALA" or the "Company"), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof). H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering were approximately $10 million, before deducting the placement agent fees and other offering expenses payable by the Company. Th

    12/5/25 2:36:59 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

    ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("KALA" or the "Company"), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 5, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to th

    12/4/25 10:45:14 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KALA BIO downgraded by Mizuho with a new price target

    Mizuho downgraded KALA BIO from Outperform to Neutral and set a new price target of $1.50

    9/30/25 9:48:28 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by H.C. Wainwright

    H.C. Wainwright downgraded KALA BIO from Buy to Neutral

    9/29/25 1:25:35 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded KALA BIO from Buy to Neutral

    9/29/25 9:48:46 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    SEC Filings

    View All

    KALA BIO Inc. filed SEC Form 8-K: Leadership Update

    8-K - KALA BIO, Inc. (0001479419) (Filer)

    2/5/26 4:05:29 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - KALA BIO, Inc. (0001479419) (Filer)

    2/2/26 6:01:30 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by KALA BIO Inc.

    DEFA14A - KALA BIO, Inc. (0001479419) (Filer)

    1/26/26 4:05:07 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $2,000,000 worth of shares (310,559 units at $6.44) (SEC Form 4)

    4 - KALA BIO, Inc. (0001479419) (Issuer)

    12/31/24 4:00:18 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Lazar David E.

    4 - KALA BIO, Inc. (0001479419) (Issuer)

    12/22/25 5:18:14 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Oxford Finance Llc claimed ownership of 1,620,000 shares (SEC Form 3)

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    12/3/25 5:00:59 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Lazar David E. claimed no ownership of stock in the company (SEC Form 3)

    3/A - KALA BIO, Inc. (0001479419) (Issuer)

    12/2/25 6:30:40 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Leadership Updates

    Live Leadership Updates

    View All

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Announces Chief Executive Officer Transition

    ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

    2/12/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

    -- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 ---- Received FDA Fast Track designation for KPI-012 for the treatment of PCED ---- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and sever

    5/9/23 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by KALA BIO Inc.

    SC 13G - KALA BIO, Inc. (0001479419) (Subject)

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by KALA BIO Inc.

    SC 13D - KALA BIO, Inc. (0001479419) (Subject)

    7/8/24 8:54:55 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by KALA BIO Inc.

    SC 13D - KALA BIO, Inc. (0001479419) (Subject)

    6/28/24 4:11:51 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Financials

    Live finance-specific insights

    View All

    Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

    ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on August 30, 2022. The

    8/18/22 4:01:00 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    -- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and prov

    8/11/22 7:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

    ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651. To access a live webcast and subsequent archived recording of the call, please visit the "Presentations" se

    8/8/22 9:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care